Prosecution Insights
Last updated: November 04, 2026
Application No. 18/554,463

METHOD FOR PRODUCING TAGATOSE BY IMMOBILIZING MULTIPLE ENZYMES BY USING ARTIFICIAL OIL BODY

Final Rejection §103§112
Filed
Oct 07, 2023
Priority
Apr 07, 2021 — CN 212110370762.0 +1 more
Examiner
KANE, TREVOR LOGAN
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tianjin Yeahe Biotechnology Co., Ltd.
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
78 granted / 113 resolved
+9.0% vs TC avg
Strong +53% interview lift
Without
With
+53.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
26 currently pending
Career history
150
Total Applications
across all art units

Statute-Specific Performance

§101
5.7%
-34.3% vs TC avg
§103
43.0%
+3.0% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
29.4%
-10.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 113 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of the species of sesame oleosin, SEQ ID NO 1, and Thermotoga maritima in the reply filed on 3/11/26 is acknowledged. Response to Amendment This action is written in response to applicant’s amendments received on 7/29/26. The rejection of the claims under 35 USC 112(b) is overcome by amendment. Any objection or rejection not reiterated herein has been overcome by amendment. Amended claims 1-2,4,7-11 and 14 are under examination herein. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The IDS filed on 10/7/23, 10/23/25, and 3/6/26 have been fully considered except where references have been lined through. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. New rejection necessitated by amendment. Claim 10 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 10 requires a standard 200w laboratory cell disruptor and a standard 10 cm horizontal centrifuge rotor. This is not supported in the specification. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. New rejection necessitated by amendment. Claims 1-2 4, 7-10 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim is directed to a product and a process. This is indefinite, see MPEP 2173.05(p) II. Regarding claim 14, Claim 14 recites the limitation " the use". There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-3, 5-7, 10-14 are rejected under 35 U.S.C. 103 as being unpatentable over Wichelecki (US20190017083A1) in view of Tseng ("Immobilization of Clostridium cellulolyticum D-psicose 3-epimerase on artificial oil bodies." Journal of agricultural and food chemistry 62.28 (2014): 6771-6776) and Chiang et al. "A useful method integrating production and immobilization of recombinant cellulase." Applied microbiology and biotechnology 97.20 (2013): 9185-9192. (Year: 2013). Regarding claims 1 and 10-11, Wichelecki teaches enzymatic production of tagatose (abstract). Wichelecki teaches that that a series of enzymes can be used to create the tagatose (fig 2 and [0018]). Wichelecki teaches that alpha-glucan phosphorylase, phosphoglucomutase, phosphoglucoisomerase, fructose 6-phosphate epimerase and tagatose 6-phosphate phosphatase are used (fig 2 and [0018]). While Wichelecki uses the nomenclature of fructose 6-phosphate epimerase rather than the claimed tagatose 6-phosphate 4-empimerase, instant specification [0016] indicates that any enzyme capable of catalyzing the reaction of fructose-6-phosphate into tagatose-6-phosphate is a tagatose 6-phosphate 4-empimerase. As Wichelecki teaches that fructose 6-phosphate epimerase catalyzing the reaction of fructose-6-phosphate into tagatose-6-phosphate is a tagatose 6-phosphate 4-empimerase, one of ordinary skill in the arts understands that the enzyme of Wichelecki is the same as the claimed enzyme. Wichelecki teaches that E. coli harboring a protein expression plasmid (singular enzyme/distinct proteins) ([0073]). Weichelecki teaches that following individual protein expression and isolation, the proteins can be mixed together (multi-enzyme complex) (example 1). Wichelecki does not explicitly teach the enzymes immobilized in an oil body or multiple enzymes present in the oil body. Tseng teaches the immobilization of epimerases in an artificial oil body for the production of a rare sugar (abstract). Tseng teaches that this method saves time, money, and is easy and effective (introduction). Tseng teaches that recombinant enzymes are coupled to an oleosin gene, expressed, and inserted into the oil body (materials and methods, fig 1). Tseng teaches sesame oleosins can be used (introduction). Tseng teaches the protein is combined with buffer, olive oil (oil body), and phospholipids, then ultrasonicated, centrifuged, and collected (materials and methods). While Tseng does not explicitly specify collecting the upper layer, as the components are the same as the claimed invention and the layering is simply a result of the properties of the composition, one of ordinary skill in the arts would understand that the oil body would form on the top layer and it would have been obvious to collect such layer. Wichelecki and Tseng does not explicitly teach multiple enzymes in an oil body Chiang teaches useful methods for immobilizing a recombinant multienzyme complex (cellulase) (title). Chiang teaches that individual enzymes can be expressed, purified, and co-immobilized on an artificial oil body (AOB) (multi enzyme complex supported by a single artificial oil body) (abstract, fig 1). Chiang further teaches that “AOBs-immobilized cellulase exhibited 80 % of the original activity after four consecutive reaction cycles” and that the immobilized complex had a high degree of storage stability (p. 9189, under Reusability of AOBs-bound cellulase). Chiang teaches that the AOB multi enzymes are an easy and direct method to study various combinations of enzymes (discussion). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the immobilized enzymes of Wichelecki in an oil body as taught by Tseng and Chiang. One of ordinary skill in the art would be motivated to do so because Tseng teaches that this method saves time, money, and is easy and effective. Further, one of ordinary skill in the art would be motivated to do so because these artificial oil bodies have been successfully used to immobilize multienzyme complexes. Moreover, Chiang teaches that AOB-immobilization allows for a high degree of reusability and storage stability. There would be a reasonable expectation of success as both Wichelecki, Chiang, and Tseng are in the same field of endeavor of enzymes, and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions. Regarding claim 2, Wichelecki teaches bacteria expressing the enzymes (expression vectors) can be transformed, expressed and isolated ([0070-0075]). Wichelecki teaches the enzymes can be derived from Thermotoga maritima ([0076]). Wichelecki teaches the enzymes are thermostable ([0074]). Chiang teaches the each enzyme can be coupled to oleosin (fusion proteins, single oleosin and single enzyme), transformed into recombinant bacteria and expressed (materials and methods). Regarding claim 7, Wichelecki teaches that the enzymes can be present in any desired ratio to maximize the product yield ([0032]). Therefore, the mass ratios of the enzymes is a result effective variable and one of ordinary skill in the arts would be motivated to experiment with the mass ratios of the enzymes to arrive at the claimed concentration. See MPEP 2144.05 II. B. Regarding claim 11, Wichelecki teaches the process is carried out at 40-70oc ([0014]). Wichelecki teaches the phosphate (inorganic phosphate) can be in the range of 0-150mM ([0035]). This overlaps the claimed range and therefore the claimed range is prima facia obvious. Wichelecki teaches the starch can be degraded (debranched) using enzymes ([0038-0042]). Wichelecki teaches the debranching enzymes can be used at 5 U/mL (example 5) Wichelecki teaches HEPES buffer in the range of 5-8 pH can be used ([0062]). Wichelecki teaches that 100 mM HEPES can be used (example 5). Wichelecki teaches that 5 mM MgCl2 and 0.5 mM ZnCl2 can be used (example 5). Wichelecki teaches that starch or its derivative including maltodextrin can be used ([0009]). Wichelecki teaches that maltodextrin can be used at a concentration of 50 g/L (example 13). MPEP 2144.04 states that “selection of any order of performing process steps is prima facie obvious in the absence of new or unexpected results” Regarding claim 14, Tseng teaches that the artificial oil body comprising enzymes can be recycled (Reusability of the AOB-lmmobilized CC-DPEase). Claims 8 -9 are rejected under 35 U.S.C. 103 as being unpatentable over Wichelecki (US20190017083A1) and Tseng ("Immobilization of Clostridium cellulolyticum D-psicose 3-epimerase on artificial oil bodies." Journal of agricultural and food chemistry 62.28 (2014): 6771-6776) as applied to claims 1-3, 5-7 and9-14 above, and further in view of Wijesundera (US20140024714A1). Regarding claim 8, Tseng teaches olive oil can be used (vegetable oil containing triglyceride) (material and methods). Wichelecki and Tseng do not explicitly teach where the phospholipid is lecithin. Wijesundera teaches artificial oil bodies (abstract). Wijesundera teaches lecithin can be used as a phospholipid for creation of the oil bodies ([120-121]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to use lecithin in the invention of Tseng and Wichelecki above. One of ordinary skill in the art would be motivated to do so because these phospholipids have been successfully used to create artificial oil bodies, and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results to one of ordinary skill in the art. There would be a reasonable expectation of success as both Tseng and Wijesundera are in the same field of endeavor of oil bodies. Regarding claim 9, the claim is a product by process claim and as such is only limited by the product and not the process steps needed to make the product. In instant case, the mass ratios are construed as the process, and the product only needs to comprise the enzyme oil body with triglyceride and lecithin which is met by the combination of references in claim 8. There are no clear mass ratio limitations regarding the final product. Response to Arguments Applicant's arguments filed 7/29/26 have been fully considered but they are not persuasive. Applicant argues the species election (election restriction). The traversal is on the ground(s) that the species are biological alternatives and not a serious burden to examine. This is not found persuasive because a serious burden exists, see the restriction requirement mailed on 1/13/26 (e.g., individual species would require separate searches and would require different prior art references). Applicant argues that the cited art does not teach multiple enzymes in an AOB (p9 second paragraph, p9-10 bridging paragraph). This argument is moot in view of the new grounds of rejection above. Applicant further argues a series of unclaimed purported unexpected results. This is not persuasive as the argued efficiency is not present in the claims or in affidavit of unexpected results. Applicant bears the burden of producing objective evidence establishing that any purported differences in results are in fact unexpected and unobvious and of both statistical and practical significance (MPEP 716.02(b)). Such evidence must be factually supported by an appropriate affidavit or declaration to be of probative value (MPEP 716.01 (a)). The arguments of counsel cannot take the place of evidence in the record (MPEP 716.01 (a)). Moreover, any unexpected results must be commensurate in scope with the claims the evidence is offered to support (MPEP 716.02(d)). Applicant argues there is no reasonable motivation to combine the art (p9 3rd paragraph). Tseng teaches that this method saves time, money, and is easy and effective (introduction). Moreover, Chiang teaches that AOB-immobilization allows for a high degree of reusability and storage stability. See the rejection above for detail. Applicant argues that long term recyclability is important (p9 4th paragraph). This is not persuasive as the argued recyclability is not present in the claims or in affidavit of unexpected results. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TREVOR L KANE whose telephone number is (571)272-0265. The examiner can normally be reached M-F 7:00 am-4:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Louise Humphrey can be reached at 571-272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TREVOR KANE/ Examiner, Art Unit 1657 /ROBERT J YAMASAKI/ Primary Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Oct 07, 2023
Application Filed
May 06, 2026
Non-Final Rejection mailed — §103, §112
Jul 29, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782358
REAGENT FOR MEASURING B-GLUCAN, METHOD FOR PRODUCING SAME AND USE THEREOF
2y 9m to grant Granted Nov 03, 2026
Patent 12767938
POLYPEPTIDE FOR THE THERAPY OF GLOMERULAR KIDNEY DISEASE AND ANALYSIS OF THE COURSE AND PROGNOSIS OF DEPENDENT SYN-DROMES
4y 1m to grant Granted Oct 20, 2026
Patent 12758592
MAGNETIC BACTERIA, NON-THERAPEUTIC AND THERAPEUTIC USES THEREOF
4y 8m to grant Granted Oct 13, 2026
Patent 12735732
Method for preparing ultra-low molecular weight Dendrobium oligosaccharides by enzymatic hydrolysis and its application
1y 11m to grant Granted Sep 15, 2026
Patent 12721349
METHOD FOR PROMOTING BACTERIAL CELL WALL DEGRADATION
4y 11m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
99%
With Interview (+53.4%)
3y 4m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 113 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month